Literature DB >> 21782516

Open source drug discovery--a new paradigm of collaborative research in tuberculosis drug development.

Anshu Bhardwaj1, Vinod Scaria, Gajendra Pal Singh Raghava, Andrew Michael Lynn, Nagasuma Chandra, Sulagna Banerjee, Muthukurussi V Raghunandanan, Vikas Pandey, Bhupesh Taneja, Jyoti Yadav, Debasis Dash, Jaijit Bhattacharya, Amit Misra, Anil Kumar, Srinivasan Ramachandran, Zakir Thomas, Samir K Brahmachari.   

Abstract

It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21782516     DOI: 10.1016/j.tube.2011.06.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  22 in total

Review 1.  Global phenotypic screening for antimalarials.

Authors:  W Armand Guiguemde; Anang A Shelat; Jose F Garcia-Bustos; Thierry T Diagana; Francisco-Javier Gamo; R Kiplin Guy
Journal:  Chem Biol       Date:  2012-01-27

Review 2.  Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors:  Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  Enabling policy planning and innovation management through patent information and co-authorship network analyses: a study of tuberculosis in Brazil.

Authors:  Alexandre Guimarães Vasconcellos; Carlos Medicis Morel
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

4.  Open source drug discovery in practice: a case study.

Authors:  Christine Årdal; John-Arne Røttingen
Journal:  PLoS Negl Trop Dis       Date:  2012-09-20

5.  Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis.

Authors:  Rohit Vashisht; Anupam Kumar Mondal; Akanksha Jain; Anup Shah; Priti Vishnoi; Priyanka Priyadarshini; Kausik Bhattacharyya; Harsha Rohira; Ashwini G Bhat; Anurag Passi; Keya Mukherjee; Kumari Sonal Choudhary; Vikas Kumar; Anshula Arora; Prabhakaran Munusamy; Ahalyaa Subramanian; Aparna Venkatachalam; S Gayathri; Sweety Raj; Vijaya Chitra; Kaveri Verma; Salman Zaheer; J Balaganesh; Malarvizhi Gurusamy; Mohammed Razeeth; Ilamathi Raja; Madhumohan Thandapani; Vishal Mevada; Raviraj Soni; Shruti Rana; Girish Muthagadhalli Ramanna; Swetha Raghavan; Sunil N Subramanya; Trupti Kholia; Rajesh Patel; Varsha Bhavnani; Lakavath Chiranjeevi; Soumi Sengupta; Pankaj Kumar Singh; Naresh Atray; Swati Gandhi; Tiruvayipati Suma Avasthi; Shefin Nisthar; Meenakshi Anurag; Pratibha Sharma; Yasha Hasija; Debasis Dash; Arun Sharma; Vinod Scaria; Zakir Thomas; Nagasuma Chandra; Samir K Brahmachari; Anshu Bhardwaj
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

6.  The structure of Rv3717 reveals a novel amidase from Mycobacterium tuberculosis.

Authors:  Atul Kumar; Sanjiv Kumar; Dilip Kumar; Arpit Mishra; Rikeshwer P Dewangan; Priyanka Shrivastava; Srinivasan Ramachandran; Bhupesh Taneja
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-11-19

7.  Open Drug Discovery Teams: A Chemistry Mobile App for Collaboration.

Authors:  Sean Ekins; Alex M Clark; Antony J Williams
Journal:  Mol Inform       Date:  2012-08-06       Impact factor: 3.353

Review 8.  Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases.

Authors:  Minna Allarakhia
Journal:  Drug Des Devel Ther       Date:  2013-08-08       Impact factor: 4.162

9.  Biological diversity in the patent system.

Authors:  Paul Oldham; Stephen Hall; Oscar Forero
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

Review 10.  Open source drug discovery - a limited tutorial.

Authors:  Murray N Robertson; Paul M Ylioja; Alice E Williamson; Michael Woelfle; Michael Robins; Katrina A Badiola; Paul Willis; Piero Olliaro; Timothy N C Wells; Matthew H Todd
Journal:  Parasitology       Date:  2013-08-28       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.